Bayer's Clock is Ticking: A Supreme Court Verdict, a New CFO, and a Stroke Drug That Works

Bayer awaits a US Supreme Court decision on Roundup liability, debuts promising stroke drug data, and welcomes a new CFO amid a major restructuring.

The month of June is shaping up to be a defining moment for Bayer. Within weeks, the German conglomerate expects a ruling from the US Supreme Court that could cap its multibillion-dollar Roundup liability, while a new finance chief takes the helm and the company publishes compelling Phase III data for a potential blockbuster stroke drug. For CEO Bill Anderson, it is a convergence of risk and reward that will determine the company’s trajectory for years.

A Scientific First, But No Commercial Green Light Yet

The most encouraging news for Bayer’s pipeline comes from the New England Journal of Medicine. The full results of the OCEANIC-STROKE trial show that its experimental drug, Asundexian, reduced the risk of ischemic stroke by 26% compared to a placebo, without a significant increase in major bleeding. This marks the first successful Phase III study for a Factor XIa inhibitor in this indication, involving more than 12,000 participants globally.

The US Food and Drug Administration has already granted Asundexian a Fast Track designation, but the drug remains an investigational product with no approvals anywhere. The data now serve as the foundation for formal regulatory discussions. While the scientific community is impressed, the market has yet to price in this success.

The Legal Sword of Damocles

The reason for the market’s caution is the persistent legal overhang. The Supreme Court is currently hearing arguments on whether federal law—specifically the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA)—preempts state-level warning requirements for Roundup. Bayer argues that since the EPA approved the label without a cancer warning, the lawsuits alleging a link to Non-Hodgkin lymphoma are invalid. The Trump administration has filed a brief supporting Bayer’s position.

A decision is expected by the end of June. If it sides with Bayer, it would clear the path for the company’s proposed $7.25 billion settlement to resolve current and future claims. If not, the legal drain continues. Bayer has already set aside provisions of nearly €11.8 billion for Roundup litigation and secured an €8 billion credit line. For the current year, management expects cash outflows of around €5 billion.

A New Financial Steward

The legal calendar aligns almost perfectly with a leadership change in the finance department. Wolfgang Nickl, Bayer’s CFO for nearly a decade, retired at the annual general meeting last week. His successor, Judith Hartmann, takes over on June 1. She brings experience from Engie and Bertelsmann and steps into a company undergoing a radical restructuring.

Under the “Dynamic Shared Ownership” model, CEO Anderson has been slashing layers of management and cutting thousands of positions. The goal is to achieve sustainable cost savings of €2 billion by the end of 2026. The supervisory board has backed this strategy, recently extending Anderson’s contract through early 2029.

The Agricultural Pivot

Beyond the courtroom and the boardroom, Bayer’s crop science division is quietly repositioning itself. On the annual general meeting on April 24, Anderson outlined a five-year framework focused on competitiveness and cash generation, rather than volume growth. The company is shifting away from legacy chemical products toward higher-margin offerings.

One example is the insecticide Plenexos, launched in Colombia in late 2025, with a Brazilian approval expected in 2026. Larger innovations, such as the short-stature corn PRECEON™ and the herbicide Icafolin, are not expected to generate significant momentum until 2027.

The Numbers Tell a Mixed Story

Financially, Bayer is in a solid but not spectacular position. Revenue for 2025 came in at €45.6 billion. For 2026, the company targets net sales between €45 billion and €47 billion, with adjusted EBITDA between €9.6 billion and €10.1 billion.

Free cash flow, however, took a hit, falling by roughly a third to €2.1 billion. Net debt dropped to just under €29.8 billion. The balance sheet is manageable, but the legal overhang weighs heavily on the stock.

The shares currently trade at around €38, down roughly 7% on the week and about 22% below their 52-week high of nearly €49. Portfolio manager Markus Manns of Union Investment sums up the disconnect: “Operationally, Bayer is in a much stronger position than the share price suggests.” He argues that the stock needs two things to re-rate: a victory at the Supreme Court and acceptance of the $7.25 billion settlement. Until then, the market will remain focused on the legal risk, not the pipeline progress.